0QF.XETRA Moderna, Inc.

Healthcare Biotechnology XETRA Stock Exchange
220.40 EUR
Close of Nov 6, 2026
19.37 245.55
Market cap
EUR 88.0B
P/E
-
P/B
13.70x
ROE
-62.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0QF.XETRA undervalued?

Graham number

The Graham number of Moderna, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Moderna, Inc. fundamental analysis

No fundamental analysis for Moderna, Inc. yet.

Moderna, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines;…

Full company profile